HealthySwaps
AI-driven precision medicine for complex chronic diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
N/A | Seed | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (34 %) | - | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (89 %) | (953 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (94 %) | (953 %) | - | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
RowAnalytics Ltd rebranded to PrecisionLife, an AI-enabled precision medicine company. Founded by Dr. Steve Gardner, who serves as CEO, the company is headquartered near Oxford, UK, with operations in the USA, Denmark, and Poland. PrecisionLife utilizes a combinatorial analytics platform to analyze multi-modal patient data, including genomic, phenotypic, and clinical information, to gain deeper insights into the mechanisms of complex chronic diseases.
The company's core technology stratifies patient populations to identify novel drug targets, biomarkers, and candidates for drug repurposing. This approach is applied to over 50 complex diseases, including ALS, Alzheimer's disease, and Long COVID. PrecisionLife's business model is centered on a scalable early-stage partnering model with pharmaceutical companies, biotech firms, healthcare providers, and disease charities. It develops and out-licenses validated assets with comprehensive biological data packages to de-risk and accelerate clinical trials. The company also offers solutions for indication extension, systematically identifying new uses for existing drugs.
PrecisionLife has formed strategic collaborations with entities such as Ono Pharmaceutical for CNS disorders, Metrodora Institute for chronic conditions like Long COVID, and Absci for AI-enabled drug development. The company secured seed funding in 2018 from investors including Astia Angels and Wheatsheaf Group and announced the first close of its Series A financing in early 2022 to expand its drug discovery pipeline and commercial partnerships.
Keywords: precision medicine, combinatorial analytics, chronic diseases, drug discovery, patient stratification, biomarkers, AI in healthcare, multi-omic data, genomic analysis, biopharma partnerships, clinical trial acceleration, drug repurposing, disease biology, personalized healthcare, techbio, CNS disorders, rare diseases, data analytics, life sciences, therapeutic targets